Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
Novartis, 8 Oct 2015
Accessed on 13 Oct 2015 from https://www.novartis.com/news/media-releases/long-term-efficacy-gilenya®-reinforced-new-no-evidence-disease-activity-neda-4.